What is the clinical evidence from this study?

Study design: Review. Population: Arrhythmia. Intervention: Class III antiarrhythmic agents.

What question did this study set out to answer?

To evaluate the therapeutic concept of controlling cardiac arrhythmias by prolonging repolarization and examine the distinct electrophysiological profiles of pure versus complex class III antiarrhythmic agents.

November 2, 1993European Heart Journal

Arrhythmia control by prolonging repolarization: The concept and its potential therapeutic impact

View Full Paper

Ask AI

Bookmark

Key result

Class III antiarrhythmic agents prolong myocardial repolarization and exhibit a varying spectrum of antifibrillatory and proarrhythmic actions, requiring careful balance in new drug development.

Key Points

To evaluate the therapeutic concept of controlling cardiac arrhythmias by prolonging repolarization and examine the distinct electrophysiological profiles of pure versus complex class III antiarrhythmic agents.
Synthesized experimental and clinical evidence comparing the electropharmacological actions of class I agents, beta blockers, and class III drugs.
Evaluated the mechanistic differences between selective 'pure' class III agents (such as dofetilide and sematilide) and multi-action agents (such as amiodarone and sotalol).
Class III agents exert antifibrillatory effects primarily by prolonging repolarization with minimal effects on conduction, though they carry a variable risk of inducing torsade de pointes.
Pure class III agents selectively target specific ion channels, whereas complex agents like sotalol and amiodarone combine repolarization prolongation with antiadrenergic activity.
Drug development requires striking a balance between antifibrillatory efficacy and proarrhythmic liability across simple and complex electropharmacologic profiles.

Structured PICO

Intervention

Class III antiarrhythmic agents (amiodarone, sotalol, sematilide, dofetilide, E-4031)

This review highlights the need to balance antifibrillatory properties and proarrhythmic risks (such as torsade de pointes) in the development and use of class III antiarrhythmic agents.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports cautious use of class III agents with proarrhythmia monitoring; leaves open optimal efficacy-safety balance for new drug development.

Cite This Study

Bramah N. Singh (1993) conducted a review in Arrhythmia. Class III antiarrhythmic agents was evaluated. Class III antiarrhythmic agents prolong myocardial repolarization and exhibit a varying spectrum of antifibrillatory and proarrhythmic actions, requiring careful balance in new drug development.

synapsesocial.com/papers/6a97e63b2855ae6cf374d806 https://doi.org/10.1093/eurheartj/14.suppl_h.14

View Full Paper

Ask AI

Bookmark

Implication

Supports cautious use of class III agents with proarrhythmia monitoring; leaves open optimal efficacy-safety balance for new drug development.

Arrhythmia control by prolonging repolarization: The concept and its potential therapeutic impact

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Arrhythmia control by prolonging repolarization: The concept and its potential therapeutic impact

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider